Molecular Mechanisms Linking Empagliflozin to Renal Protection in the LLC-PK1 Model of Diabetic Nephropathy.
Vjera NincevicMilorad ZjalicTomislav KizivatTea Omanovic KolaricMartina SmolicEdi RođakMarina ČovićLucija Kuna RoguljicRobert SmolicAleksandar VčevInes Bilić ĆurčićPublished in: Biomedicines (2022)
Renoprotective effects of empagliflozin, in this LLC-PK1 cell model of DN, are mediated via activation of the Akt/GSK-3 signalling pathway, thus reducing oxidative stress-induced damage, as well as enhanced SMAD7 expression leading to downregulation of TGF-β1, one of the key mediators of inflammation and fibrosis.